Skip to main content

. 1977;70(Suppl 3):10–12. doi: 10.1177/00359157770700S306

Preparation of and clinical experiences with trien for the treatment of Wilson's disease in absolute intolerance of D-penicillamine.

H Harders ¹, E Cohnen ¹

PMCID: PMC1543601 PMID: 122652

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

Bucur I., Hasselgren K. H. Letter: Treatment of Wilson's disease. Lancet. 1975 Dec 13;2(7946):1218–1218. doi: 10.1016/s0140-6736(75)92721-x. [DOI] [PubMed] [Google Scholar]
Dixon H. B., Gibbs K., Walshe J. M. Preparation of triethylenetetramine dihydrochloride for the treatment of Wilson's disease. Lancet. 1972 Apr 15;1(7755):853–853. doi: 10.1016/s0140-6736(72)90845-8. [DOI] [PubMed] [Google Scholar]
Dubois R. S., Rodgerson D. O., Slovis T. L., Hambidge K. M., Bianchi T. A. Triethylene tetramine dihydrochloride in Wilson's disease. Lancet. 1970 Oct 10;2(7676):775–775. doi: 10.1016/s0140-6736(70)90251-5. [DOI] [PubMed] [Google Scholar]
Gelmers H. J., Troost J., Willemse J. Wilson's disease: modification by L-DOPA. Neuropadiatrie. 1973 Dec;4(4):453–457. doi: 10.1055/s-0028-1091761. [DOI] [PubMed] [Google Scholar]
Gibbs K., Walshe J. M. Letter: Treatment of Wilson's disease. Br Med J. 1975 Dec 20;4(5998):706–706. doi: 10.1136/bmj.4.5998.706. [DOI] [PMC free article] [PubMed] [Google Scholar]
Lyle W. H. Letter: More on "orphan" drugs. N Engl J Med. 1975 Apr 10;292(15):813–814. [PubMed] [Google Scholar]
Peterson C. M., Cerami A. Letter: "Orphan-drug" development - whose responsibility? N Engl J Med. 1975 Jan 16;292(3):162–162. doi: 10.1056/nejm197501162920315. [DOI] [PubMed] [Google Scholar]
Walshe J. M. Management of penicillamine nephropathy in Wilson's disease: a new chelating agent. Lancet. 1969 Dec 27;2(7635):1401–1402. doi: 10.1016/s0140-6736(69)90940-4. [DOI] [PubMed] [Google Scholar]

ACTIONS

RESOURCES